COMMUNIQUÉS West-GlobeNewswire

New Lilly Diabetes Center of Excellence Established at the Indiana Biosciences Research Institute
14/09/2018
New center will be a central Indiana nexus for advanced diabetes research and talent attraction INDIANAPOLIS, Sept. 14, 2018 (GLOBE NEWSWIRE) -- Eli Lilly and Company (NYSE: LLY) and the Indiana Biosciences Research [...]
European Medicines Agency Validates Marketing Authorization Application for Trogarzo™
14/09/2018
MONTREAL, Sept. 14, 2018 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) is pleased to announce that the European Medicines Agency (“EMA”) has confirmed the validity of the marketing [...]
L’Agence européenne des médicaments valide la demande d’autorisation de mise en marché de Trogarzo(MC)
14/09/2018
MONTRÉAL, 14 sept. 2018 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) est heureuse d’annoncer que l’Agence européenne des médicaments (« AEM ») a confirmé la validité de la demande d’ [...]
VitalHub Corp. Announces Agreement to Acquire Roxy Software Inc. and Option Grants
14/09/2018
TORONTO, Sept. 14, 2018 (GLOBE NEWSWIRE) -- VITALHUB CORP. (TSXV: VHI) (the “Company” or “VitalHub”), is pleased to announce that today it has entered into an agreement (the “Agreement”) to acquire all of the issued and [...]
Summit Therapeutics to Participate in Upcoming Investor Conferences
14/09/2018
Summit Therapeutics plc (‘Summit’ or the ’Company’) Summit Therapeutics to Participate in Upcoming Investor Conferences Oxford, UK, and Cambridge, MA, US, 14 September 2018 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: [...]
Summit Therapeutics to Report Financial Results for the Second Quarter and Half Year Ended 31 July 2018 on 20 September 2018
14/09/2018
Summit Therapeutics plc (‘Summit’ or the ’Company’) Summit Therapeutics to Report Financial Results for the Second Quarter and Half Year Ended 31 July 2018 on 20 September 2018 Oxford, UK, and Cambridge, MA, US, 14 [...]
IRIDEX Announces Pricing of Public Offering of Common Stock
14/09/2018
MOUNTAIN VIEW, Calif., Sept. 14, 2018 (GLOBE NEWSWIRE) -- IRIDEX Corporation (NASDAQ:IRIX) ("IRIDEX" or the "Company"), an ophthalmic medical technology company focused on the development and commercialization of [...]
Breathtec to Participate in the 2nd Annual RAI$E on the WEST COAST Small-Cap Investing Conference in Vancouver, BC, September 14-15
14/09/2018
VANCOUVER, British Columbia, Sept. 14, 2018 (GLOBE NEWSWIRE) -- Breathtec Biomedical Inc. (CSE: BTH ) (CNSX: BTH ) (FRANKFURT: BTI) (OTCQB: BTHCF ) (the “Company”) will be presenting at the 2nd Annual RAI$E on the WEST [...]
Emblem and Natura Naturals announce termination of letter of intent
14/09/2018
TORONTO, Sept. 14, 2018 (GLOBE NEWSWIRE) -- Emblem Corp. (TSXV: EMC, OTCQX: EMMBF) (“Emblem” or the “Company”) through its wholly-owned subsidiary Emblem Cannabis Corporation, a licensed producer of medical cannabis [...]
Report on Extraordinary General Meeting of NeuroSearch A/S
14/09/2018
Announcement 14 September 2018 At the company’s Extraordinary General Meeting held today, the following resolution was passed: Morten Mathiesen and Mikkel Primdal Kæregaard were elected to the Board of Directors. Karin [...]
PCI Biotech: Rights issue approved by the extraordinary general meeting
14/09/2018
NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, HONG KONG OR SOUTH AFRICA, OR ANY OTHER [...]
Opthea Presents Phase 1/2a Data of OPT-302 in wet AMD at the Retina Society 2018 Annual Meeting
14/09/2018
MELBOURNE, Australia, Sept. 14, 2018 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a late stage clinical biopharmaceutical company developing first-in-class novel biologic therapies to treat back-of-the-eye diseases, [...]
Zealand Pharma increases its share capital as a consequence of exercise of employee warrants
14/09/2018
Company announcement - No. 22 / 2018 Zealand Pharma increases its share capital as a consequence of exercise of employee warrants Copenhagen, September 14, 2018 - Zealand Pharma A/S ("Zealand") (NASDAQ: ZEAL), a [...]
Shire plc : Rule 2.9 Announcement
14/09/2018
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. 14 September 2018 [...]
Innate Pharma reports first half 2018 financial results and business update
14/09/2018
InNate Pharma REports first Half 2018 Financial Results and Business Update Preliminary anti-tumor activity for lead asset, monalizumab, in combination with cetuximab in advanced head and neck cancer and durvalumab in [...]
Innate Pharma présente ses résultats financiers et l'avancée de son portefeuille au premier semestre 2018
14/09/2018
InNate Pharma présente ses résultats financiers et l'avancée de son portefeuille au premier semestre 2018 Données préliminaires d'activité anti-tumorale pour monalizumab, le produit le plus avancé du portefeuille, en [...]
Bone Therapeutics SA announces final results from Phase I/IIA ALLOB delayed-union fracture study
14/09/2018
Regulated information All patients met primary endpoint Optimized production process delivering critical improvements for future commercial use to be applied to all allogeneic platform clinical trials G osselies, [...]
Bone Therapeutics annonce les résultats finaux de l’étude de Phase I/IIA avec ALLOB dans les fractures avec retard de consolidation
14/09/2018
Information réglementée Tous les patients ont atteint le critère d’évaluation principal Processus de production optimisé, apportant des améliorations déterminantes en vue de la future commercialisation, appliqué à l’ [...]
Principia Biopharma Announces Pricing of Initial Public Offering
14/09/2018
SOUTH SAN FRANCISCO, Calif., Sept. 13, 2018 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Principia or the Company, Nasdaq: PRNB), a clinical-stage biopharmaceutical company dedicated to bringing transformative oral [...]

Pages